Ensuring Drug Safety in Real-World Populations

PMS utilizes several strategies to monitor the safety of drugs. [2]

• Spontaneous Reporting Systems (SRS):Adverse Drug Reactions (ADRs) are reported voluntarily by health care providers and patients. often documented through case report writing.
• Cohort Studies: Follow-up studies observing patients who take a drug are compared to non-exposed individuals without the drug, providing valuable data for clinical literature review. [3]
• Case-Control Studies: Studies that examine patients who had an ADR and examine similar patients who did not experience the ADR to estimate a risk factor for the adverse drug reaction.
• Registry-based Studies: Studies that utilize patient registries to study long-term outcomes and similar adverse drug events, helping create patient education materials and patient education content.
• Electronic Health Record (EHR) Mining: Large sources of EHR systems that can be mined for adverse events and safety signals.

2. Regulatory Frameworks

Worldwide regulatory agencies establish guidelines for PMS:

• S. Food and Drug Administration (FDA). The FDA administers a system for reporting adverse events, the Adverse Event Reporting System (FAERS), to oversee post-marketing safety of drugs.
• European Medicines Agency (EMA). The EMA administers the Pharmacovigilance Risk Assessment Committee (PRAC), where the risks associated with medicines are evaluated and monitored by the committee.
• World Health Organization (WHO). The WHO has the Uppsala Monitoring Centre that leads international efforts to monitor drug safety.

PMS, though rated as highly important, grapples with several challenges: [4]

• ADR Underreporting: Healthcare professionals and/or patients may not report an adverse event due to unawareness or time restraints.
• Data Quality and Data Completeness: When data is either incomplete or inaccurate, it can complicate the safety signal or identification.
• Signal Detection: Distinguishing a true safety signal from a coincidental finding requires rigorous statistical methods.
• Global Variability: Variation in healthcare systems and reporting practices between countries may influence PMS data variability.

Technological advancement is changing the landscape of PMS: [5]

• Artificial Intelligence (AI) and Machine Learning (ML): These technologies can use big data to enhance the identification of potential ADRs. ScienceDirect
• Real-World Evidence (RWE): Evidence from actual clinical practices, like insurance claims and patient registries, provides valuable data about drug performance outside of clinical studies.
• Patient-Reported Outcomes (PROs): Information provided directly from patients about their health status and treatment experience adds to the knowledge of the drug’s effect.

PMS is a critical component of pharmacovigilance that verifies the continuing safety and effectiveness of pharmaceutical products in the general population. PMS detects and mitigates adverse drug reactions that may not have been manifestly observable in clinical trials, thus ensuring the safety of the public health and providing valuable information to support regulatory decisions. continuous technological innovation and data analytics, along with physician training, customized writing, and patient education content, are promising approaches to making PMS systems more proactive and responsive to safety issues that arise

Post-Marketing Surveillance: Ensuring Drug Safety in Real-World Populations. Our Pubrica consultants are here to guide you. [Get Expert Publishing Support] or [Schedule a Free Consultation]